# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Diagnostics Advisory Committee (DAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** 16 February 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Brian Shine (Chair) Present for all items
2. Keith Abrams Present for items 2 – 2.2.3
3. Ghada Ahmed Present for all items
4. Joy Allen Present for items 1 - 1.3.3
5. John Cairns Present for items 1.2.3 - 2.2.3
6. Sam Creavin Present for all items
7. Diane Davies Present for all items
8. Neil Hawkins Present for all items
9. Rashmi Kumar Present for all items
10. Patrick McGinley Present for all items
11. Brendan Meyer Present for all items
12. Radha Ramachandran Present for all items
13. Anne Scott Present for all items
14. Karen Sennett Present for all items
15. Matt Stevenson Present for all items

NICE staff present

Rebecca Albrow, Associate Director, Diagnostics Assessment Present for all items

Programme (DAP)

Judith Shore, Health Technology Assessment Adviser, DAP Present for items 1 - 1.3.3

Thomas Walker, Health Technology Assessment Adviser, DAP Present for items 2 - 2.2.3

Anam Khan, Health Technology Assessment Analyst, DAP Present for items 1 - 1.3.3

Vera Unwin, Health Technology Assessment Analyst, DAP Present for items 2 – 2.2.3

Toni Gasse, Project Manager, DAP Present for all items

Harriet Wilson, Project Manager, DAP Present for all items

Alex Sexton, Administrator, DAP Present for all items

External assessment group representatives present

Dwayne Boyers, Senior Research Fellow, Aberdeen Present for items 1 - 1.2.6

Health Technology Assessment Group

Miriam Brazzelli, Reader, Aberdeen Health Technology Present for items 1 - 1.2.6

Assessment Group

Lucy Beresford, Research Fellow, Centre for Reviews Present for items 2 – 2.1.5  
and Dissemination, University of York

**Specialist Committee Members present**

Joanna Atkin, Lay specialist committee member Present for items 1 - 1.3.3

Ian Chetter, Chair of Surgery, Hull York Medical Present for items 1 - 1.3.3  
School, University of Hull

Patrick Coughlin, Consultant Vascular Surgeon, Present for items 1 - 1.3.3  
Leeds Vascular Institute

Alun Davies, Professor of Vascular Surgery, Present for items 1 - 1.3.3  
Imperial College London

Colin Davies, Clinical Lead (Leg Ulcers), Present for items 1 - 1.3.3  
Gloucestershire Hospitals NHS Foundation Trust

Alan Elstone, Vascular Advanced Clinical Present for items 1 - 1.3.3  
Practitioner, Derriford Hospital, Plymouth

Jane Tod-Hunter, Advanced Vascular Nurse Practitioner, Present for items 1 to 1.3.3  
North Cumbria Integrated Care Trust

Pauline Bagnall, Uro-oncology Nurse Specialist, Present for items 2 - 2.2.3

Northumbria Healthcare NHS Foundation Trust

Sanjeev Madan, Consultant Urological Surgeon, Present for items 2 - 2.2.3  
Dartford & Gravesham NHS Trust

Santhanam Sundar, Consultant Clinical Oncologist, Present for items 2 - 2.2.3  
Nottingham University Hospitals NHS trust

Graeme Spencer, Lay specialist Present for items 2 - 2.2.3

Observers present

Rosalee Mason , Coordinator, Meetings in Public Present for items 1 - 1.2.6 and items 2 - 2.1.5

Ben Gregory, Finance/Business Analyst Present for items 1 - 1.3.3

Mark Rasburn, Public Involvement Adviser Present for all items

Edgar Masanga, Business Analyst Present for items 2 - 2.2.3

Ruth Melville, Senior Medical Editor Present for items 1 – 1.3.3

Anna Sparshatt, Senior Medical Editor Present for items 2 - 2.2.3

## Minutes

### Assessment of Automated ankle brachial pressure index measurement devices for assessing peripheral arterial disease in people with leg ulceration

### The Chair welcomed members of the committee and other attendees present to the meeting.

The Chair welcomed Anne Scott as a new standing committee member.

The Chair noted apologies from standing committee members Rebecca Allcock, Keith Abrams, Michael Messenger, and Jonathan Weir-McCall, and from specialist committee members Ben Cooper and David Russell.

* 1. The committee approved the minutes of the committee meeting held on 16 December 2022 and 18 January 2023.
  2. Part 1 – Open session
     1. The Chair welcomed external assessment group representatives, members of the public, and company representatives from BlueDop Medical Ltd, Huntleigh Healthcare, Microlife Health Management Ltd and MESI Ltd.
     2. The Chair asked all committee members to declare any new relevant interests in relation to the topic being considered in addition to those declared in advance of the meeting. The following standing committee members who were attending the meeting had notified these interests in advance of the meeting:

Joy Allen declared a financial interest as she is an employee of Roche Diagnostics. It was agreed that this interest would not prevent Joy Allen from participating in the meeting.

John Cairns declared a financial interest as he had provided advice on HTA of epilepsy treatments at a meeting organised by PWC Switzerland (completed Dec 2021). It was agreed that this interest would not prevent John Cairns from participating in the meeting.

Patrick McGinley declared a financial interest as he is an employee of Maidstone and Tunbridge Wells NHS Trust. He is an Associate to MTechAccess, providing advice on NHS funding. He also declared non-financial professional and personal interests as he is a Strategic Council member of the All-Party Parliamentary Group (APPG) on Obesity. He is also the Honorary Treasurer for the Association for Study of Obesity (ASO). It was agreed that these interests would not prevent Patrick McGinley from participating in the meeting.

The following specialist committee members who were attending the meeting had notified these interests in advance of the meeting:

Patrick Coughlin declared financial interests as he undertakes private practice. He also declared an indirect interest as he is a Council member of the Vascular Society of GB and Ireland. He also declared non-financial professional and personal interests as he works with the surgical medtech co-op in Leeds (https://surgicalmic.nihr.ac.uk/) who were approached by Bluedop last year; some introductory meetings were held but no payment was involved and no project was progressed no assistance provided. It was agreed that these interests would not prevent Patrick Coughlin from participating in the meeting.

Alun Davies declared a financial interest due to private practice in vascular surgery. He also declared non-financial professional and personal interests as he is Joint Chief investigator on an NIHR trial evaluating non-invasive techniques in diabetic foot evaluation. He is involved in NMES evaluation in diabetic peripheral neuropathy (grant funding to his employer from Atergy) and he is involved with Healthshare, developing a communities platform for diabetes care. It was agreed that these interests would not prevent Alun Davies from participating in the meeting.

Alan Elstone declared non-financial professional and personal interests as he clinical national nursing lead for the NHSE&I Abdominal Aortic Aneurysm Screening programme in England (NAAASP), and he is a member of the Editorial Board for Wounds UK Journal. It was agreed that these interests would not prevent Alan Elstone from participating in the meeting.

Jane Tod-Hunter declared financial interests as she is PI for VENUS 6 study, recruiting patients for the study, and PI for DAVE study, recruiting patients for the study. She also declared non-financial professional and personal interests as she is Vice President of the Society of Vascular Nurses. It was agreed that these interests would not prevent Jane Tod-Hunter from participating in the meeting.

* + 1. The Committee proceeded to discuss the comments made during the public consultation for the topic ‘Automated ankle brachial pressure index measurement devices for assessing peripheral arterial disease in people with leg ulceration’. The Committee was asked if there were any specific equality issues to consider in relation to this assessment.
    2. The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.
    3. The Chair thanked the manufacturer representatives, the EAG and public observers for their attendance at the meeting.
    4. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
  1. Part 2 - Closed session
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Diagnostics Guidance Document (DGD). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the DGD in line with their decisions.

### Assessment of MRI fusion biopsy in people with suspected prostate cancer

### The Chair welcomed members of the committee and other attendees present to the meeting.

The Chair noted apologies from standing committee members Rebecca Allcock, Michael Messenger and Jonathan Weir-McCall, and from specialist committee members Steve Allen, Oliver Hulson, Lillian White, and Hide Yamamoto. He also noted that standing committee member Joy Allen was not attending due to a conflict of interest.

* 1. Part 1 – Open session

The Chair welcomed external assessment group representatives, members of the public, and company representatives from BK Medical, Focal Healthcare, Kebomed UK/Koelist, MedCom GmbH and Phillips Ltd.

* + 1. The Chair asked all committee members to declare any new relevant interests in relation to the topic being considered in addition to those declared in advance of the meeting. The following standing committee members who were attending the meeting had notified these interests in advance of the meeting:

Keith Abrams declared a financial interest as he is a Partner and Director, Visible Analytics Limited, a HTA Consultancy company, but he has not been involved in any projects which involve a diagnostic technology. He has been, and is, involved via Visible Analytics Limited with projects for therapeutic products in prostate cancer, but these do not involve diagnostics for any of the companies involved with this assessment. It was agreed that this interest would not prevent Keith Abrams from participating in the meeting.

Joy Allen declared a financial interest as she is an employee of Roche Diagnostics, UK and Ireland. Roche Diagnostics manufacturer the Elecsys® total PSA and free PSA, Tumor marker tests to support early detection and monitoring of prostate cancer. She also declared non-financial professional and personal interests as she was a co-applicant on NIHR i4i Connect Award: ‘GlycoScore: Superior prostate cancer diagnosis using a simple blood test’ (interest ceased August 2021). She further declared an indirect interest as Roche Diagnostics UK hold an NDA with Philips regarding community based diagnostics (although there had been no live discussions on this topic). It was agreed that these interests meant Joy Allen could not participate in the discussions and she did not attend the meeting.

John Cairns declared a financial interest due to his participation in a double-blinded focus group organized by PwC Switzerland on an epilepsy treatment (interest ceased December 2021). It was agreed that this interest would not prevent John Cairns from participating in the meeting.

Patrick McGinley declared a financial interest as he is a Faculty Member of MTech Access, providing advice on NHS finance structure, pricing and tariff developments. He also declared non-financial professional and personal interests as he is a Strategic Council member of the All-Party Parliamentary Group (APPG) on Obesity; he is Honorary Treasurer for the Association for Study of Obesity (ASO) and he is a Member of Obesity Policy Engagement Network UK (OPEN UK). It was agreed that these interests would not prevent Patrick McGinley from participating in the meeting.

The following specialist committee members who were attending the meeting had notified these interests in advance of the meeting:

Pauline Bagnall declared financial interests as she had attended an education meeting funded by Bayer (interest ceased September 2021); she had participated in a team building event sponsored by MSD in May 2022, and she works for the Prostate Cancer Research as a Clinical Nurse Specialist one day a week. She also declared non-financial professional and personal interests as she is a trustee of the British Association of Urological Nursing, a member of the National Prostate Cancer Audit Clinical Reference Group and a member of Prostate Cancer Risk Management Programme. It was agreed that these interests would not prevent Pauline Bagnall from participating in the meeting.

Sanjeev Madan declared financial interest as he undertakes private practice; he had received remuneration for attending Bayer advisory board meetings and speaker engagements in February, March and August 2021; he had received speaker fees from Ipsen in June 2021 and from Laborie in July 2021. It was agreed that these interests would not prevent Sanjeev Madan from participating in the meeting.

Santhanam Sundar declared financial interests as he had received registration fee sponsorship for the ESMO conference from BSM in September 2022; and he does private medical practice. He also declared non-financial professional and personal interests as he is a council member of Royal College of Radiology. It was agreed that these interests would not prevent Santhanam Sundar from participating in the meeting.

* + 1. The Committee proceeded to discuss the comments made during the public consultation for the topic ‘MRI fusion biopsy in people with suspected prostate cancer’. The Committee was asked if there were any specific equality issues to consider in relation to this assessment.
    2. The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.
    3. The Chair thanked the manufacturer representatives, the EAG and public observers for their attendance at the meeting.
    4. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
  1. Part 2 - Closed session
     1. The committee discussed confidential information submitted for this item.
     2. The committee then agreed on the content of the Diagnostics Guidance Document (DGD). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the DGD in line with their decisions.

### Date of the next meeting

The next meeting of the Diagnostics Advisory Committee (next topic) will be held on 2 March 2023.